In patients suffering from depression who were treated with escitalopram, concomitant 3-week administration of the MR agonist fludrocortisone led to a faster response to the antidepressant treatment compared to patients who received the MR antagonist spironolactone or placebo (Otte et al. 2010). The gene discussed is NR3C2; the disease is major depressive disorder.